Journal Article
. 2021 Sep; 12(19):2551-2563.
doi: 10.1111/1759-7714.14136.

Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1

Wei Tian 1 Yinping Sun 2 Yuping Cheng 2 Xiao Ma 3 Weina Du 4 Wenna Shi 5 Qisen Guo 6 
Affiliations
  • PMID: 34469060
  •     31 References
  •     1 citations

Abstract

Background: Recent studies have found that programmed death ligand 1 (PD-L1) might be involved in chemotherapy resistance in non-small cell lung cancer (NSCLC). Arsenic sulfide (As4 S4 ) has been recognized to have antitumor activities and enhance the cytotoxic effect of chemotherapy drugs. In this study, we aimed to verify the relationship between PD-L1 and cisplatin (DDP) resistance and identify whether As4 S4 could reverse DDP resistance through targeting PD-L1 in NSCLC.

Methods: The effect of As4 S4 and DDP on cell proliferation and apoptosis was investigated in NSCLC cell lines. The expression of p53 and PD-L1 proteins was measured by western blotting analysis. The levels of miR-34a-5p, miR-34a-3p and PD-L1 in cells were measured by real-time qPCR analysis. Mouse xenograft models were established by inoculation with A549/DDP (DDP-resistant) cells.

Results: Depletion of PD-L1 inhibited DDP resistance in A549/DDP and H1299/DDP cells. As4 S4 was capable of sensitizing A549/DDP cells to DDP by enhancing apoptosis. As4 S4 upregulated p53 expression and downregulated PD-L1 expression in A549/DDP cells. As4 S4 increased miR-34a-5p level in A549/DDP cells. Inhibition of p53 by PFT-α partially restored the levels of PD-L1 and miR-34a-5p. Pretreatment with PFT-α suppressed the apoptosis rate induced by cotreatment of As4 S4 and DDP in A549/DDP cells. Cotreatment of DDP and As4 S4 notably reduced the tumor size when compared with DDP treatment alone in vivo.

Conclusions: Upregulation of PD-L1 was correlated with DDP resistance in NSCLC cells. Mechanistic analyses indicated that As4 S4 might sensitize NSCLC cells to DDP through targeting p53/miR-34a-5p/PD-L1 axis.

Keywords: As4S4; NSCLC; PD-L1; chemoresistance; cisplatin.

Alternative mechanisms of miR-34a regulation in cancer.
Eva Slabáková, Zoran Culig, Ján Remšík, Karel Souček.
Cell Death Dis, 2017 Oct 13; 8(10). PMID: 29022903    Free PMC article.
Highly Cited. Review.
Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
Panpan Zhang, Yuanyuan Ma, +10 authors, Yue Yang.
Cancer Sci, 2016 Sep 02; 107(11). PMID: 27581532    Free PMC article.
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics.
Akintunde Akinleye, Zoaib Rasool.
J Hematol Oncol, 2019 Sep 07; 12(1). PMID: 31488176    Free PMC article.
Highly Cited. Review.
Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis.
A Parsons, A Daley, R Begh, P Aveyard.
BMJ, 2010 Jan 23; 340. PMID: 20093278    Free PMC article.
Highly Cited. Systematic Review.
Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
Mariko Ishibashi, Hideto Tamura, +7 authors, Koiti Inokuchi.
Cancer Immunol Res, 2016 Jul 22; 4(9). PMID: 27440711
MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells.
Y Zuo, W Zheng, +3 authors, X S Yang.
Neoplasma, 2019 Nov 30; 67(1). PMID: 31777260
Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth.
Lian Zhang, Yingying Tong, +2 authors, Siyu Chen.
Drug Des Devel Ther, 2015 Nov 21; 9. PMID: 26586936    Free PMC article.
Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.
Wei Tian, Yinping Sun, +4 authors, Qisen Guo.
Thorac Cancer, 2021 Sep 02; 12(19). PMID: 34469060    Free PMC article.
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
Haidong Dong, Scott E Strome, +10 authors, Lieping Chen.
Nat Med, 2002 Jul 02; 8(8). PMID: 12091876
Highly Cited.
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Barbara Melosky, Rosalyn Juergens, +5 authors, Quincy Chu.
Oncologist, 2019 May 30; 25(1). PMID: 31138727    Free PMC article.
Tumor cell-associated immune checkpoint molecules - Drivers of malignancy and stemness.
Fabrizio Marcucci, Cristiano Rumio, Angelo Corti.
Biochim Biophys Acta Rev Cancer, 2017 Oct 24; 1868(2). PMID: 29056539
Review.
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.
H Tamura, M Ishibashi, +11 authors, K Ogata.
Leukemia, 2012 Jul 26; 27(2). PMID: 22828443
Highly Cited.
Realgar (As4S4) nanoparticles and arsenic trioxide (As2O3) induced autophagy and apoptosis in human melanoma cells in vitro.
M Pastorek, P Gronesova, +6 authors, J Sedlak.
Neoplasma, 2014 Aug 26; 61(6). PMID: 25150315
The cellular response to p53: the decision between life and death.
R V Sionov, Y Haupt.
Oncogene, 1999 Nov 11; 18(45). PMID: 10557106
Highly Cited. Review.
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, +18 authors, IMpower150 Study Group.
N Engl J Med, 2018 Jun 05; 378(24). PMID: 29863955
Highly Cited.
Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report.
Dao-Pei Lu, Jing-Ying Qiu, +4 authors, Shan-Shan Chen.
Blood, 2002 Apr 20; 99(9). PMID: 11964275
Systems biology of cisplatin resistance: past, present and future.
L Galluzzi, I Vitale, +5 authors, G Kroemer.
Cell Death Dis, 2014 May 31; 5. PMID: 24874729    Free PMC article.
Highly Cited. Review.
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.
Krzysztof M Zak, Radoslaw Kitel, +6 authors, Tad A Holak.
Structure, 2015 Nov 26; 23(12). PMID: 26602187    Free PMC article.
Highly Cited.
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Xiaofeng Jiang, Jun Zhou, +2 authors, F Stephen Hodi.
Clin Cancer Res, 2012 Oct 26; 19(3). PMID: 23095323
Highly Cited.
The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells.
Dong Young Kang, Nipin Sp, +7 authors, Young Mok Yang.
Cancers (Basel), 2020 Mar 25; 12(3). PMID: 32204508    Free PMC article.
MicroRNA function: multiple mechanisms for a tiny RNA?
Ramesh S Pillai.
RNA, 2005 Nov 30; 11(12). PMID: 16314451    Free PMC article.
Highly Cited. Review.
Realgar-induced apoptosis and differentiation in all-trans retinoic acid (ATRA)-sensitive NB4 and ATRA-resistant MR2 cells.
Siyu Chen, Yi Fang, +2 authors, Xinmin Li.
Int J Oncol, 2011 Dec 03; 40(4). PMID: 22134377    Free PMC article.
PDL1 Regulation by p53 via miR-34.
Maria Angelica Cortez, Cristina Ivan, +15 authors, James W Welsh.
J Natl Cancer Inst, 2015 Nov 19; 108(1). PMID: 26577528    Free PMC article.
Highly Cited.
The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer.
Yu Fujita, Shigehiro Yagishita, +11 authors, Takahiro Ochiya.
Mol Ther, 2015 Jan 20; 23(4). PMID: 25597412    Free PMC article.
Highly Cited.
ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia.
M H G P Raaijmakers.
Leukemia, 2007 Jul 28; 21(10). PMID: 17657220
Review.
Arsenic sulfide, the main component of realgar, a traditional Chinese medicine, induces apoptosis of gastric cancer cells in vitro and in vivo.
Lian Zhang, Wei Tian, +3 authors, Siyu Chen.
Drug Des Devel Ther, 2015 Jan 08; 9. PMID: 25565771    Free PMC article.
PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways.
Shengwei Liu, Shuang Chen, +4 authors, Dalin Li.
Oncotarget, 2017 Dec 17; 8(59). PMID: 29245948    Free PMC article.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, +3 authors, Ahmedin Jemal.
CA Cancer J Clin, 2018 Sep 13; 68(6). PMID: 30207593
Highly Cited.
Cancer immunotherapy using checkpoint blockade.
Antoni Ribas, Jedd D Wolchok.
Science, 2018 Mar 24; 359(6382). PMID: 29567705    Free PMC article.
Highly Cited. Review.
Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule.
Hazem Ghebeh, Cynthia Lehe, +9 authors, Said Dermime.
Breast Cancer Res, 2010 Jul 16; 12(4). PMID: 20626886    Free PMC article.
The application and mechanism of PD pathway blockade for cancer therapy.
Xing Wang, Shan Huang, +2 authors, Xiaoliang Wu.
Postgrad Med J, 2017 Sep 25; 94(1107). PMID: 28942432
Review.
Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.
Wei Tian, Yinping Sun, +4 authors, Qisen Guo.
Thorac Cancer, 2021 Sep 02; 12(19). PMID: 34469060    Free PMC article.